USANA Health (USNA) AI Stock Analysis

• Market Cap: $527.14M
• Dividend Yield: N/A
• Average Volume (3M): 134.98K
• Price to Earnings (P/E): 16.0
• Beta (1Y): 0.97
• Revenue Growth: 2.75%
• EPS Growth: -37.25%
• Country: US
• Employees: 1,700
• Sector: Consumer Defensive
• Sector Strength: 68
• Industry: Packaged Foods
• EPS (TTM): 0.74
• Shares Outstanding: 18,271,835
• 10 Day Avg. Volume: 130,250
• 30 Day Avg. Volume: 134,983
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 0.55
• Enterprise Value/Gross Profit: 0.68
• Enterprise Value/Ebitda: 5.24
• 1Y Price Target: $35.00
• Price Target Upside: 19.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: $35.00 ▲(19.37% Upside)

USANA Health benefits from strong earnings performance and strategic initiatives, though it faces financial challenges with declining revenues and customer numbers. The technical outlook is mixed, and valuation is moderate. The positive momentum from recent earnings and initiatives supports a stable outlook.

USANA Health Business Overview & Revenue Model

Company Description

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

How the Company Makes Money

USANA generates revenue primarily through the sale of its nutritional supplements and personal care products. The company's revenue model is based on a direct selling approach, where independent distributors purchase products at wholesale prices and sell them at retail prices, keeping the difference as profit. This creates a dual revenue stream: the sale of products to consumers and the commissions paid to distributors based on their sales performance and the sales of their recruited team members. Additionally, USANA benefits from a strong brand reputation and customer loyalty, which contribute to repeat purchases. The company also invests in marketing strategies and partnerships that enhance its visibility and product reach, further supporting its revenue growth.

USANA Health Financial Statement Overview

Summary

USANA Health shows strong gross margins and a solid balance sheet with low leverage, but faces challenges with declining revenues, reduced net profit margins, and lower free cash flow growth. The overall financial position is stable, though improvement in revenue and net income is necessary.

Income Statement

USANA Health has experienced a declining revenue trend over the last few years, with a revenue decrease of approximately 7% from 2023 to 2024. The gross profit margin in 2024 was strong at around 81%, indicating efficient cost management. However, net profit margin decreased to about 4.92% in 2024 compared to 6.92% in 2023, reflecting pressure on net income. Despite this, the company maintains a solid EBIT margin at 7.76% in 2024. Overall, the company shows strong gross margins but faces challenges with declining revenues and net profitability.

Balance Sheet

USANA Health's balance sheet reflects a strong equity position with an equity ratio of approximately 71.1% in 2024, indicating financial stability and low leverage. The debt-to-equity ratio remains low at 0.04, demonstrating conservative financial management and limited reliance on debt. Return on equity decreased to 7.9% in 2024 from 12.8% in 2023, indicating reduced profitability on equity investments. Overall, the company's balance sheet is robust, supported by strong equity and low debt levels, although ROE has seen a decline.

Cash Flow

The cash flow analysis shows a modest decrease in free cash flow from 2023 to 2024 by about 9.3%. The operating cash flow to net income ratio is healthy, suggesting efficient cash generation relative to net income. However, the free cash flow to net income ratio has declined, reflecting less cash available after capital expenditures. Despite these challenges, USANA Health continues to generate positive operating cash flow. Overall, cash flows are positive, but there is a downward trend in free cash flow growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	854.50M	921.01M	998.60M	1.19B	1.13B
Gross Profit	693.29M	744.32M	804.71M	968.57M	925.53M
EBITDA	98.86M	123.11M	130.22M	192.89M	200.96M
Net Income	42.03M	63.79M	69.35M	116.50M	124.66M
Balance Sheet
Total Assets	748.19M	632.76M	596.55M	577.74M	640.89M
Cash, Cash Equivalents and Short-Term Investments	181.77M	330.42M	288.42M	239.83M	311.92M
Total Debt	29.01M	13.21M	6.89M	7.08M	8.62M
Total Liabilities	161.86M	135.56M	162.08M	182.62M	199.24M
Stockholders Equity	532.11M	497.20M	434.47M	395.12M	441.65M
Cash Flow
Free Cash Flow	50.92M	56.15M	93.50M	108.46M	145.31M
Operating Cash Flow	60.99M	70.64M	103.90M	121.23M	160.40M
Investing Cash Flow	-213.09M	-11.97M	-12.37M	-14.19M	-33.96M
Financing Cash Flow	9.55M	-14.24M	-30.09M	-181.41M	-59.44M

USANA Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 29.32
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USNA, the sentiment is Neutral. The current price of 29.32 is below the 20-day moving average (MA) of 30.43, below the 50-day MA of 30.72, and below the 200-day MA of 32.08, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 43.57 is Neutral, neither overbought nor oversold. The STOCH value of 21.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for USNA.

USANA Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LFVN	74 Outperform	$173.21M	19.71	30.11%	1.20%	8.22%	159.71%
HLF	72 Outperform	$917.64M	2.80	-31.74%	―	-2.25%	288.79%
NATR	72 Outperform	$283.93M	21.59	9.15%	―	4.33%	-6.33%
USNA	70 Outperform	$527.14M	16.01	6.54%	―	2.75%	-37.25%
STKL	59 Neutral	$737.48M	―	-1.34%	―	10.90%	96.02%
Sector *	54 Neutral	C$5.40B	6.78	11.95%	3.36%	5.02%	-2.86%
HAIN	46 Neutral	$147.11M	―	-31.83%	―	-8.50%	-186.18%

USANA Health Corporate Events

USANA Health Reports 11% Sales Increase in Q2 2025

USANA Health Sciences reported an 11% increase in net sales for the second quarter of 2025 compared to the same period in 2024, despite a slight decline in net earnings. The company is maintaining its fiscal year 2025 outlook and continues to execute its growth strategy, including enhancements to its direct sales model and the launch of new products. Hiya, USANA’s direct-to-consumer business, performed well with strong year-over-year growth and a new partnership with Disney. The company also repurchased shares and ended the quarter with a strong cash position and no debt.

The most recent analyst rating on (USNA) stock is a Hold with a $65.00 price target. To see the full list of analyst forecasts on USANA Health stock, see the USNA Stock Forecast page.

USANA Health Secures New Credit Agreement with Bank

On June 27, 2025, USANA Health Sciences, Inc. entered into a Third Amended and Restated Credit Agreement with Bank of America, providing a revolving credit limit of up to $75 million, with an option to increase by $200 million. This agreement is secured by the pledge of capital stock of USANA’s subsidiaries and includes financial covenants related to EBITDA and debt ratios. The agreement allows for flexibility in financial operations, as it does not restrict cash dividends or share repurchases, but outlines events of default that could lead to immediate repayment demands.

The most recent analyst rating on (USNA) stock is a Hold with a $65.00 price target. To see the full list of analyst forecasts on USANA Health stock, see the USNA Stock Forecast page.

USANA Health Holds Annual Shareholders Meeting

On May 19, 2025, USANA Health conducted its Annual Meeting of Shareholders, where approximately 92% of the company’s shares were represented. During the meeting, shareholders elected eight individuals to the Board of Directors, approved the 2025 Equity Incentive Plan, ratified KPMG LLP as the independent accounting firm for fiscal year 2025, and approved executive compensation on an advisory basis.

The most recent analyst rating on (USNA) stock is a Hold with a $65.00 price target. To see the full list of analyst forecasts on USANA Health stock, see the USNA Stock Forecast page.